Levulinic Acid

Levulinic Acid

SCHEMBL113572

CC(=O)CCC(=O)O.CC(=O)CCC(=O)O

nearest known ligand 1.00 ✓ in ChEMBL — recovers established targets

Full drug profile on Sugi Atlas →

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ LMNA P02545 4/20 1.00
▸ SLC15A2 Q16348 1/20 1.00
▸ ALDH1A1 P00352 1/20 0.71
▸ EGLN1 Q9GZT9 6/20 0.64
▸ ALKBH5 Q6P6C2 1/20 0.64
▸ SUCNR1 Q9BXA5 1/20 0.64
▸ PHF8 Q9UPP1 7/20 0.60
▸ KDM2A Q9Y2K7 7/20 0.60
▸ KDM5C P41229 4/20 0.60
▸ KDM4E B2RXH2 3/20 0.60
▸ KDM6B O15054 3/20 0.60
▸ FFAR3 O14843 2/20 0.50
▸ HDAC3 O15379 1/20 0.50
▸ HDAC1 Q13547 1/20 0.50
▸ HDAC2 Q92769 1/20 0.50
▸ HDAC8 Q9BY41 1/20 0.50
▸ MAPK1 P28482 1/20 0.47
▸ SLC13A3 Q8WWT9 1/20 0.47
▸ OR51E2 Q9H255 1/20 0.47
▸ SLC22A6 Q4U2R8 1/20 0.47

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
Levulinic Acid SCHEMBL30530258 1.00 — —
Levulinic Acid SCHEMBL27931545 1.00 LMNA (1.00) LMNASLC15A2ALDH1A1EGLN1ALKBH5
Levulinic Acid SCHEMBL20868 1.00 — —
Levulinic Acid SCHEMBL2231609 0.97 — —
Levulinic Acid SCHEMBL21815654 0.97 — —
Levulinic Acid SCHEMBL12971398 0.97 — —
Levulinic Acid SCHEMBL21815797 0.97 — —
Levulinic Acid SCHEMBL21815633 0.97 — —
Levulinic Acid SCHEMBL10835733 0.97 — —
Levulinic Acid SCHEMBL439420 0.97 — —

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 480 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20260028539-A1 COMPOSITIONS FOR PRODUCTION OF OLEFINS, TERPENES, AROMATICS AND CYCLOALIPHATICS AND METHODS THEREFOR, AND PRODUCTS THEREFROM VISOLIS INC (US) 2026-01-29 — — US claimed
EP-3063164-B1 SYNTHETIC ROUTE TO 2'-DEOXY-2',2'-DIFLUOROTETRAHYDROURIDINES OTSUKA PHARMA CO LTD (JP) 2018-12-05 — — EP claimed
US-20120094836-A1 Biocide Compositions (III) COGNIS IP MANAGEMENT GMBH (DE) 2012-04-19 — — US claimed
WO-2011026580-A2 BIOCIDE COMPOSITIONS (IV) COGNIS IP MANAGEMENT GMBH (DE) 2011-03-10 — — WO claimed
EP-2292092-A1 Biocide compositions comprising esters of ketocarboxylic acids Cognis IP Management GmbH (DE) 2011-03-09 — — EP claimed
EP-2269451-A1 Biocide compositions (III) Cognis IP Management GmbH (DE) 2011-01-05 — — EP claimed
US-20260092130-A1 PROCESS FOR SYNTHESIZING POLYMER COMPOSITIONS FROM STARTING MATERIALS COMPRISING A DOUBLE BOND VISOLIS INC (US) 2026-04-02 — — US disclosed
US-20260092228-A1 COMPOSITIONS FOR FUEL BLENDING MADE BY A SUSTAINABLE PROCESS, AND SUSTAINABLE FUEL COMPOSITIONS THEREFROM VISOLIS INC (US) 2026-04-02 — — US disclosed
US-20260092023-A1 PROCESS SYNTHESIZING SUSTAINABLE AVIATION FUEL COMPOSITIONS VISOLIS INC (US) 2026-04-02 — — US disclosed
US-20260055330-A1 HIGH ENERGY DENSITY ROCKET FUEL COMPOSITIONS VISOLIS INC (US) 2026-02-26 — — US disclosed
WO-2026022791-A1 HIGH ENERGY DENSITY ROCKET FUEL COMPOSITIONS Visolis, Inc. (US) 2026-01-29 — — WO disclosed
US-20260028540-A1 PROCESS SYNTHESIZING SUSTAINABLE AVIATION FUEL COMPOSITIONS FROM STARTING MATERIALS COMPRISING A DOUBLE BOND VISOLIS INC (US) 2026-01-29 — — US disclosed
US-20260028545-A1 SUSTAINABLE AVIATION FUEL COMPOSITIONS VISOLIS INC (US) 2026-01-29 — — US disclosed
US-20010051632-A1 Phenyl-substituted indolizines and tetrahydroindolizines ORTHO MCNEIL PHARMACEUTICAL, INC. 2001-12-13 — — US disclosed
US-20010044439-A1 Method for using 2-aryloxyalkylaminobenzoxazoles and 2-aryloxyalkylaminobenzothiazoles as H3 antagonists ORTHO MCNEIL PHARMACEUTICAL, INC. 2001-11-22 — — US disclosed
WO-2001074815-A2 PHENYL-SUBSTITUTED IMIDAZOPYRIDINES ORTHO MCNEIL PHARMACEUTICAL, INC. (US) 2001-10-11 — — WO disclosed
WO-2001074814-A1 PHENYL-SUBSTITUTED INDOLIZINE DERIVATIVES AND THEIR USE AS HISTAMINE H3 LIGANDS ORTHO MCNEIL PHARMACEUTICAL, INC. (US) 2001-10-11 — — WO disclosed
WO-2001074813-A2 METHOD FOR USING 2- OR 3-ARYL SUBSTITUTED IMIDAZO[1,2-a] PYRIDINES AS H3 ANTAGONISTS ORTHO MCNEIL PHARMACEUTICAL, INC. (US) 2001-10-11 — — WO disclosed
WO-2001074773-A2 PHENYL-SUBSTITUTED INDOLES AS HISTAMINE H3-RECEPTOR ANTAGONISTS ORTHO MCNEIL PHARMACEUTICAL, INC. (US) 2001-10-11 — — WO disclosed
WO-2001074810-A2 METHOD FOR USING 2-ARYLOXYALKYLAMINOBENZOXAZOLES AND 2-ARYLOXYALKYLAMINOBENZOTHIAZOLES AS H3 ANTAGONISTS ORTHO MCNEIL PHARMACEUTICAL, INC. (US) 2001-10-11 — — WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (9 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20260092228-A1 COMPOSITIONS FOR FUEL BLENDING MADE BY A SUSTAINABLE PROCESS, AND SUSTAINABLE FUEL COMPOSITIONS THEREFROM CYP4F12, CYP4F11, CYP4F8 LMNA 2643/4885SLC15A2 2596/4885ALDH1A1 700/4885
US-20260028540-A1 PROCESS SYNTHESIZING SUSTAINABLE AVIATION FUEL COMPOSITIONS FROM STARTING MATERIALS COMPRISING A DOUBLE BOND AHR, COASY, YAP1 LMNA 1431/4885SLC15A2 2187/4885ALDH1A1 741/4885
US-20260092023-A1 PROCESS SYNTHESIZING SUSTAINABLE AVIATION FUEL COMPOSITIONS CYP4A11, HMGCR, FADS1 LMNA 1499/4885SLC15A2 2255/4885ALDH1A1 569/4885
US-20010044439-A1 Method for using 2-aryloxyalkylaminobenzoxazoles and 2-aryloxyalkylaminobenzothiazoles as H3 antagonists HRH3, HRH4, HRH2 LMNA 3594/4885SLC15A2 3995/4885ALDH1A1 1270/4885
US-20260055330-A1 HIGH ENERGY DENSITY ROCKET FUEL COMPOSITIONS HMGCR, CYP46A1, GGPS1 LMNA 1842/4885SLC15A2 3145/4885ALDH1A1 1657/4885
US-20260092130-A1 PROCESS FOR SYNTHESIZING POLYMER COMPOSITIONS FROM STARTING MATERIALS COMPRISING A DOUBLE BOND SAMM50, MAX, HSF1 LMNA 2269/4885SLC15A2 3436/4885ALDH1A1 1681/4885
US-20260028539-A1 COMPOSITIONS FOR PRODUCTION OF OLEFINS, TERPENES, AROMATICS AND CYCLOALIPHATICS AND METHODS THEREFOR, AND PRODUCTS THEREFROM CYP4F11, FDFT1, CYP4A11 LMNA 3663/4885SLC15A2 1068/4885ALDH1A1 413/4885
US-20010051632-A1 Phenyl-substituted indolizines and tetrahydroindolizines TPH2, TPH1, IDO2 LMNA 2489/4885SLC15A2 1992/4885ALDH1A1 967/4885
US-20260028545-A1 SUSTAINABLE AVIATION FUEL COMPOSITIONS CYP4F12, CYP4F11, CYP4F8 LMNA 1546/4885SLC15A2 1906/4885ALDH1A1 694/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback